Methotrexate modulates the kinetics of adenosine in humans in vivo

Annals of the Rheumatic Diseases

Volumn 65, Issue 4, 2006, Pages 465-470

  Riksen, N P ^a   Barrera, P ^a   Van Den Broek, P H H ^a   Van Riel, P L C M ^a   Smits, P ^a   Rongen, G A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; DIPYRIDAMOLE; METHOTREXATE;

ADULT; ARTHRITIS; ARTICLE; BRACHIAL ARTERY; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME KINETICS; ERYTHROCYTE; FEMALE; FOREARM BLOOD FLOW; HUMAN; HUMAN CELL; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADENOSINE; ADENOSINE DEAMINASE; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FOREARM; HEMODYNAMIC PROCESSES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REGIONAL BLOOD FLOW; SEVERITY OF ILLNESS INDEX; VASODILATION; VASODILATOR AGENTS;

EID: 33645121428     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.048637     Document Type: Article

References (47)

1. ACR. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update, Arthritis Rheum 2002;46:328-46.
2. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmocol Rev 2005;57:163-72.
3. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35.
4. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-52.
5. Deussen A, Stappert M, Schafer S, Kelm M. Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation 1999;99:2041-7.
6. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33-9.
7. Rangen GA, Floras JS, Lenders JW, Thien T, Smits P. Cardiovascular pharmacology of purines. Clin Sci (Lond) 1997;92:13-24.
8. Silke C, Murphy MS, Buckley T, Busteed S, Molloy MG, Phelan M. The effects of caffeine ingestion on the efficacy of metfiotrexate [abstract]. Rheumatology (Oxford) 2001;40:34.
9. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2003;48:571-2.
10. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology 1999;38:997-1002.
11. Laghi-Pasini F, Capecchi PL, Di Perri T. Adenosine plasma levels after low dose methotrexate administration. J Rheumatol 1997;24:2492-3.
12. Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect or methotrexate. Inflamm Bowel Dis 1999;5:167-73.
13. Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 1999;135:813-7.
14. Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 2005;44:74-9.
15. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol 1989;256:C799-806.
16. Riksen NP, Oyen WJG, Ramakers BP, van den Broek PHH, Engbersen R, Boerman OC, et al. Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. Clin Pharmacol Ther 2005;78:52-9.
17. Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin Pharmacol Ther 1990;48:410-18.
18. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
19. Rongen GA, Ginneken E, Thien T, Lutterman JA, Smits P. Preserved vasodilator response to adenosine in insulin-dependent diabetes mellitus. Eur J Clin Invest 1996;26:192-8.
20. te Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de Kroon IF, et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995;32:218-20.
21. Petrie JR, Ueda S, Morris AD, Murray LS, Elliott HL, Connell JM. How reproducible is bilateral forearm plethysmography? Br J Clin Pharmacol 1998;45:131-9.
22. Snoeck E, Ver DK, Jacqmin P, Van Belle H, Dupont AG, Van Peer A, et al. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. J Pharmacol Exp Ther 1998;286:142-9.
23. Morabito L, Montesinos MC, Schreibman DM, Baiter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
24. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991;88:2441-5.
25. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000;43:656-63.
26. Montesinos MC, Desai A, Delano D, Chen JF, Fink JS, Jacobson MA, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
27. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
28. Nees S, Herzog V, Becker BF, Bock M, Des RC, Gerlach E. The coronary endothelium: a highly active metabolic barrier for adenosine. Basic Res Cardiol 1985;80:515-29.
29. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986;236:193-200.
30. Allegro CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5.
31. van Ede AE, Laan RF, De Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate Ann Rheum Dis 2002;61:1060-4.
32. Massaia M, Ma DD, Sylwestrowicz TA, Tidman N, Price G, Janossy G, et al. Enzymes of purine metabolism in human peripheral lymphocyte subpopulations. Clin Exp Immunol 1982;50:148-54.
33. Fontenelle LJ, Henderson JF. An enzymatic basis for the inability of erythrocytes to synthesize purine ribonucleotides de novo. Biochim Biophys Acta 1969;177:175-6.
34. Mattig S, Deussen A. Significance of adenosine metabolism of coronary smooth muscle cells. Am J Physiol Heart Circ Physiol 2001;280:H117-24.
35. van Ginneken EE, Rongen GA, Russel FG, Smits P. Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole. Clin Pharmacol Ther 2002;71:448-56.
36. Riksen NP, van Ginneken EE, Van den Broek PH, Smits P, Rongen GA. In vivo evidence against a role for adenosine in the exercise presser reflex in humans. J Appl Physiol 2005;99:522-7.
37. Biilstra P, van Ginneken EE, Huls M, Van Dijk R, Smits P, Rongen GA. Glyburide inhibits dipyridamole-induced forearm vasodilation but not adenosine-induced forearm vasodilation. Clin Pharmacol Ther 2004;75:147-56.
38. Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 2003;285:H1797-818.
39. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004;63:952-5.
40. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
41. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
42. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000;355:1616-17.
43. Asanuma H, Sanada S, Ogai A, Minamino T, Takashima S, Asakura M, et al. Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts. J Cardiovasc Pharmacol 2004;43:574-9.
44. van Ede AE, Loan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:658-65.
45. Riksen NP, Rongen GA, Blom HJ, Russel FGM, Boers GHJ, Smits P. Potential role for adenosine in the pathogenesis of the vascular complications of hyperhomocysteinemia. Cardiovasc Res 2003;59:271-6.
46. Riksen NP, Rongen GA, Boers GHJ, Blom HJ, van den Broek PHH, Smits P. Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2005;25:109-14.
47. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Bones C, Newcombe RG, et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothetial function in healthy adults. Circulation 1998;98:1848-52.